| Identification | More | [Name]
6alpha-Methylprednisolone sodium succinate | [CAS]
2375-03-3 | [Synonyms]
1,4-PREGNADIEN-6-ALPHA-METHYL-11-BETA, 17,21-TRIOL-3,20-DIONE 21-SUCCINATE, SODIUM SALT
(6alpha,11beta)-21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-6-methyl-pregna-1,4-diene-3,20-dione monosodium salt
6ALPHA-METHYL-11BETA,17ALPHA,21-TRIHYDROXY-1,4-PREGNADIENE-3,20-DIONE 21-HEMISUCCINATE SODIUM SALT
6ALPHA-METHYLPREDNISOLONE 21-HEMISUCCINATE SODIUM SALT
6-ALPHA-METHYLPREDNISOLONE SODIUM SUCCINATE
METHPREDNISOLONE SODIUM SUCCINATE
METHYLPREDNISOLONE SODIUM SUCCINATE
11-beta,17,21-trihydroxy-6-alpha-methyl-1,4-pregnadiene-3,20-dione21-(sodium
4-diene-3,20-dione,11-beta,17,21-trihydroxy-6-alpha-methyl-pregna-21-(hyd
6a-methylprednisolone21-hemisuccinate*sodium
rogensuccinate),monosodiumsalt
solu-medrol
solu-medrone
succinate)
u9088
urbasonsolubile
Pregna-1,4-diene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-6-methyl-, monosodium salt, (6alpha,11beta)-
Methylprodnisolone Sodium Succinate
Methylprednisolone Succinate BP93,USP26
6α-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-hemisuccinate | [EINECS(EC#)]
219-156-8 | [Molecular Formula]
C48H64Na2O14 | [MDL Number]
MFCD00152612 | [Molecular Weight]
910.99 | [MOL File]
2375-03-3.mol |
| Chemical Properties | Back Directory | [Melting point ]
>186°C (dec.) | [storage temp. ]
Inert atmosphere,Room Temperature | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
lyophilized powder
| [color ]
White to Off-White | [InChIKey]
FQISKWAFAHGMGT-JXAFMBTDNA-M | [SMILES]
[C@]12(C[C@@H](C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@H](C[C@]1(C)[C@@](CC[C@@]21[H])(O)C(=O)COC(=O)CCC([O-])=O)O)C)[H].[Na+] |&1:0,2,9,11,13,15,17,20,r| | [CAS DataBase Reference]
2375-03-3(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
T | [Risk Statements ]
R61:May cause harm to the unborn child.
R40:Limited evidence of a carcinogenic effect. | [Safety Statements ]
S53:Avoid exposure-obtain special instruction before use .
S22:Do not breathe dust .
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) . | [WGK Germany ]
3
| [RTECS ]
TU4154060
| [Toxicity]
LD50 oral in rat: > 5gm/kg |
| Hazard Information | Back Directory | [Description]
Methylprednisolone Sodium Succinate is the sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. It is converted into active prednisolone in the body, which activates glucocorticoid receptor-mediated gene expression. This includes inducing the synthesis of the anti-inflammatory protein IkappaB-alpha and inhibiting the synthesis of nuclear factor kappa B (NF-kappaB). As a result, proinflammatory cytokine production, such as IL-1, IL-2, and IL-6, is down-regulated, and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.
| [Uses]
6α-methylprednisolone 21-hemisuccinate sodium salt has been used to investigate glucocorticoid-induced osteonecrosis under hypoxic conditions in the MC3T3-E1 osteoblast cell line using a cell cytotoxicity assay, flow cytometry and western blotting. | [Uses]
6α-Methylprednisolone 21-Hemisuccinate is a glucocorticosteroid used in anti-inflammatory medication in the treatment of spinal cord injuries. | [Definition]
ChEBI: Methylprednisolone sodium succinate is a corticosteroid hormone. | [Brand name]
A-Methapred (Abbott);
A-Methapred (Hospira); Solu-Medrol (Pharmacia & Upjohn). | [Biochem/physiol Actions]
Glucocorticoid with slightly longer half-life than that of prednisolone. | [Side effects]
Methylprednisolone Sodium Succinate is commonly given by injection and common side effects include: injection site pain/redness/swelling, nausea, vomiting, heartburn, headache, dizziness, difficulty sleeping, appetite changes, increased sweating, acne, increased blood sugar, sore throat, fever, chills, cough, white spots in the mouth. Serious side effects manifest as abnormal weight gain, menstrual disorders, bone/joint pain, easy bruising/bleeding, mental/mood changes, fast/slow/irregular heartbeat, stomach/intestinal bleeding symptoms, seizures, liver problems, and symptoms of severe allergic reactions. Contact your doctor if any of these serious adverse symptoms occur. |
|
|